AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.

For patients with schizophrenia, repetitive transcranial magnetic stimulation (rTMS) was effective and safe in treating ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, 2024, compared to a net loss of approximately $11.3 million, or $0.48 per ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.

AbbVie’s (ABBV) two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...